Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $137
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice TargetHot
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $120 to $137.
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $120 to $137.